Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity ...

Centrally acting agents like phentermine/topiramate and naltrexone/bupropion aid weight reduction but lack MASLD-specific ...

In the SIBAMATE study, more than 60% of patients lost at least 5% of body weight after 3 months of using ...

Social determinants of health disproportionately impact patients' ability to maintain and achieve their weight loss goals.

In new guidance to medics, the European Association for the Study of Obesity praised the drugs' effectiveness and significant ...

It has been used in clinical trials of two FDA-approved medications: a first-generation weight loss drug, phentermine-topiramate, and a newer GLP-1 drug called liraglutide. Those with a high satiation ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. Injectable weight loss medications — also ...

Lowered price at retail pharmacy to expand access to overweight or obesity treatment to more patients CAMPBELL, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company ...

The European Association for the Study of Obesity recommends the GLP-1 injectables semaglutide and tirzepatide as first-line ...

Hundreds of millions of people around the road are affected by obesity, which is caused by a number of influences... | Genetics And Genomics ...

The American Association of Clinical Endocrinology (AACE) has released its 2025 Consensus Statement, introducing a ...